Her2-positive breast cancer: updating current best practice

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Integration of Taxanes in the Management of Breast Cancer

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Drug Treatment of Metastatic Breast Cancer

A Randomized, Double-blind, Placebo-controlled, Phase IIIb Trial (ATLAS) Comparing Bevacizumab Therapy with or without Erlotinib, after Completion of Chemotherapy.

Assistant Professor of Medicine Dana-Farber Cancer Institute

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

¿Qué ver en ASCO 2017?.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Alessandra Gennari, MD PhD

HER2 inhibition: when more is better?

CCO Independent Conference Highlights

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

Intention-to-treat population

CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Biologika bei onkologischen Erkrankungen älterer Menschen

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Blackwell KL et al. SABCS 2009;Abstract 61

Vahdat L et al. Proc SABCS 2012;Abstract P

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

Tab. 1 – Characteristics of patients

Swain SM et al. Proc SABCS 2012;Abstract P

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Evolving Paradigms in Recurrent/Metastatic SCCHN

Metastatic HER2+ Breast Cancer: Resistance

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

Overall Program Goals. Overall Program Goals Current Approaches.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

CDK4/6 Inhibitors in Breast Cancer:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Krop I et al. SABCS 2009;Abstract 5090.

Managing gBRCA-Positive Metastatic Breast Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Untch M et al. Proc SABCS 2010;Abstract P

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

PARP Inhibitors.

Treatment of Locally Advanced Pancreatic Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Practical Guidance on the Management of Pan-Negative NSCLC

Intervista a Filippo de Marinis

From Adjuvant to Metastatic in Melanoma

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Clinical Focus.

Presentation transcript:

Her2-positive breast cancer: updating current best practice

Program Overview

Case #1: Neoadjuvant Setting

Case #1: Treatment Recommendations

NeoSphere: Study Design and pCR Results

PFS: All Arms of Therapy, ITT Population Time From Randomization to Progressive Disease, Disease Recurrence, or Death

TRYPHAENA: Cardiac Tolerability During the Study in the Safety Period

DFS: All Arms of Therapy, ITT Population Time From Date of Surgery to Disease Progression or Death

Case #2: Adjuvant Setting

Case #2: Treatment Recommendations

Adjuvant Paclitaxel and Trastuzumab: Phase 2 Data

Case #3: Advanced First-Line

PERUSE: First-line Pertuzumab, Trastuzumab Plus Investigator’s Choice of Taxane Therapy

Case #4: Second-Line Metastatic

Case #3: Treatment Considerations

Case #4: Second-Line Metastatic — Case Evolution

Case #4: Second-Line Metastatic — Case Evolution

EMILIA: CNS Metastases at Baseline and Progression

Abbreviations

Abbreviations

Abbreviations

Abbreviations